Med2Date — Clinical Guidelines
Home Analgesia Conscious and Deep Sedation Regimens

Conscious and Deep Sedation Regimens

Last updated 1 Jun 2026 · Pain & analgesia

📋 Key Information Summary

📋
  • Drug choice depends on the procedure type, patient risk profile, desired depth of sedation, and the monitoring and airway equipment available.
  • Conscious (moderate) sedation maintains verbal contact and protective reflexes; deep sedation abolishes both and requires airway competency.
  • Nitrous oxide (50–70% N₂O/30–50% O₂) provides anxiolysis and mild analgesia via a self-administered demand-valve; onset <2 min, offset <5 min after cessation.
  • Midazolam 0.5–2.5 mg IV titrated is the most widely used benzodiazepine for procedural sedation; flumazenil should be immediately available as reversal agent.
  • Sub-dissociative ketamine (0.1–0.3 mg/kg IV) provides analgesia without respiratory depression; dissociative dosing (1–2 mg/kg IV) is used for painful paediatric procedures.
  • Propofol 0.5–1.0 mg/kg IV boluses provide rapid-onset deep sedation; carries significant risk of apnoea and hypotension — must only be administered by practitioners trained in airway management.
  • Minimum monitoring for moderate sedation: pulse oximetry, non-invasive blood pressure, continuous ECG for high-risk patients; capnography is recommended for deep sedation.
  • Fasting guidelines (2 h clear fluids, 4 h breast milk/light meal, 6 h fatty meal/standard meal) reduce aspiration risk but are not absolute prerequisites for moderate sedation in emergency settings.
  • Combination regimens (e.g. midazolam + fentanyl, or ketofol) can enhance efficacy but increase adverse event risk; use lower doses of each agent.
  • Elderly patients (>65 years) require dose reductions of 30–50% for all sedative agents due to altered pharmacokinetics and increased sensitivity.
  • Rapid sequence intubation equipment and a difficult airway trolley must be accessible whenever deep sedation is performed.
  • Aboriginal and Torres Strait Islander patients may face barriers to specialist sedation services in remote areas; procedural sedation competency for rural generalists is essential.

Introduction & Australian Epidemiology

Procedural sedation and analgesia (PSA) is one of the most commonly performed interventions in Australian emergency departments, operating theatres, dental suites, radiology departments, and procedural rooms. The Australasian College for Emergency Medicine (ACEM) estimates that over 500,000 episodes of procedural sedation are performed annually in Australian emergency departments alone, with the majority for orthopaedic manipulation, wound repair, and cardioversion.

Sedation exists on a continuum from minimal anxiolysis through moderate (conscious) sedation to deep sedation and general anaesthesia. The American Society of Anesthesiologists (ASA) sedation continuum is widely adopted in Australian practice:

Sedation Level Verbal Contact Airway Reflexes Ventilation Cardiovascular Function
Minimal (anxiolysis) Normal response Intact Unaffected Unaffected
Moderate (conscious) Purposeful response to verbal ± tactile Intact Adequate Usually maintained
Deep Purposeful response to repeated/painful stimulation May be impaired May be inadequate Usually maintained
General anaesthesia Unarousable Absent Frequently inadequate May be impaired

Australian practice is guided by the Australian and New Zealand College of Anaesthetists (ANZCA) professional documents, including PS09 (Sedation for Diagnostic and Interventional Procedures), and the ACSQHC National Safety and Quality Health Service (NSQHS) Standards. In rural and remote Australia, sedation is frequently administered by procedural general practitioners, rural generalists, and emergency medicine trainees, making competency frameworks and equipment standards critical for patient safety.

This article reviews the four most commonly used sedation agents in Australian clinical practice: nitrous oxide, midazolam, ketamine, and propofol. Each agent is discussed with respect to mechanism, dosing, adverse effects, monitoring requirements, and Australian regulatory and PBS considerations.

Nitrous Oxide

Mechanism of Action

Nitrous oxide (N₂O) is an inhaled gaseous anaesthetic agent that provides anxiolysis and mild analgesia. It acts via multiple mechanisms including NMDA receptor antagonism, endogenous opioid release, and activation of descending noradrenergic pain pathways. At concentrations of 50–70%, it produces minimal sedation with preserved airway reflexes and spontaneous ventilation.

Clinical Use

Nitrous oxide is delivered via a demand-valve (50% N₂O/50% O₂ premixed Entonox®) or via a blender capable of titrating concentrations to 70%. It is commonly used in Australian emergency departments, dental suites, obstetric units, paediatric procedural rooms, and burns dressing changes.

ℹ️
Entonox® demand valve: The patient holds the mask and self-administers via deep inhalations. The demand-valve design provides a safety feature — if the patient loses consciousness, they drop the mask and cease receiving the gas.
💨
Nitrous Oxide
Entonox® · M&H Equipment · Inhaled anaesthetic/analgesic
Adult dose 50–70% N₂O in O₂ via demand-valve; self-administered continuous inhalation
Paediatric dose 50% N₂O/O₂ (Entonox®) via face mask from age 3+; 30–50% via blender for younger children
Onset / Duration Onset 30–60 seconds; peak effect 2–5 min; offset <5 min after cessation
Renal adjustment Not required — eliminated via lungs
Hepatic adjustment Not required — minimal hepatic metabolism (<0.004%)
PBS status ⚠ Not PBS-listed (hospital/consumable supply)

Contraindications

  • Pneumothorax or suspected pneumothorax — N₂O expands gas-filled spaces (Boyle's law)
  • Within 2 weeks of intraocular gas injection (vitrectomy) — risk of gas expansion and blindness
  • Severe COPD with bullous disease
  • Bowel obstruction — expansion of intraluminal gas
  • Severe facial trauma preventing mask seal
  • Middle ear surgery or tympanic membrane grafting within 2 weeks
  • Patient unable to self-administer via demand-valve (e.g. altered cognition, age <3 years without trained operator)

Adverse Effects

  • Nausea and vomiting (5–10% of patients)
  • Dizziness, euphoria, dysphoria
  • Diffusion hypoxia — always administer 100% O₂ for 3–5 min after prolonged N₂O use
  • Megaloblastic anaemia and subacute combined degeneration of the cord with chronic/repeated exposure (occupational hazard; inhibit methionine synthase)
  • Occupational exposure — scavenging systems mandatory in Australian facilities per WHS regulations
⚠️
Occupational exposure: Chronic nitrous oxide exposure in healthcare workers inhibits methionine synthase, causing B₁₂ deficiency. Australian WHS standards require active scavenging systems and staff exposure monitoring. Pregnant healthcare workers should avoid prolonged N₂O exposure.

Midazolam

Mechanism of Action

Midazolam is a short-acting imidazobenzodiazepine that potentiates GABA-A receptor chloride conductance, producing dose-dependent anxiolysis, sedation, amnesia, and at higher doses, respiratory depression. Its water-soluble formulation causes less pain on IV injection and its rapid hepatic metabolism (CYP3A4) gives it a shorter context-sensitive half-time than diazepam.

Clinical Use

Midazolam is the most commonly used parenteral sedative in Australian emergency departments and procedural suites for moderate (conscious) sedation. It is used for orthopaedic reductions, electrical cardioversion, endoscopy, dental extractions, and paediatric procedural sedation. Intranasal midazolam (0.2–0.3 mg/kg) is used in paediatrics for needle phobia, laceration repair, and pre-procedural anxiolysis.

💊
Midazolam
Hypnovel® · Generic · Benzodiazepine
Adult dose 0.5–2.5 mg IV titrated in 0.5–1 mg increments every 2–3 min; usual total 2–5 mg; max 0.1 mg/kg (healthy) or 0.05 mg/kg (elderly/frail)
Paediatric dose IV: 0.05–0.1 mg/kg titrated; IN: 0.2–0.3 mg/kg (max 10 mg); PO: 0.25–0.5 mg/kg (max 20 mg); IM: 0.1–0.15 mg/kg
Onset / Duration IV onset 1–3 min, peak 3–5 min, duration 15–60 min; IN onset 5–10 min; PO onset 15–30 min
Renal adjustment Active metabolite (α-hydroxymidazolam) accumulates in CKD; reduce dose by 50% if eGFR <30 mL/min
Hepatic adjustment Significantly prolonged in Child-Pugh C cirrhosis; reduce dose by 50% and avoid prolonged infusion
PBS status ✔ PBS General Benefit (injection)

Reversal Agent — Flumazenil

💉
Flumazenil
Anexate® · Generic · Benzodiazepine antagonist
Adult dose 0.2 mg IV over 15 sec; repeat 0.1 mg every 60 sec; max 1 mg (total 3 mg in ICU setting)
Paediatric dose 0.01 mg/kg IV (min 0.2 mg); repeat every 1 min; max 0.05 mg/kg or 1 mg
Onset / Duration Onset 1–2 min; duration 45–90 min — may cause re-sedation when midazolam effect outlasts flumazenil
PBS status ✔ PBS General Benefit
🚨
Caution — Flumazenil and chronic benzodiazepine use: Do NOT administer flumazenil to patients on long-term benzodiazepines or with suspected benzodiazepine dependence, as this may precipitate acute withdrawal seizures. Flumazenil is contraindicated in mixed overdose with tricyclic antidepressants due to seizure threshold lowering.

Adverse Effects

  • Respiratory depression and desaturation (most significant; dose-dependent)
  • Hypotension (especially in hypovolaemia, elderly, concurrent opioids)
  • Paradoxical agitation (more common in paediatrics and elderly)
  • Anterograde amnesia (may be desirable but impairs informed consent processes)
  • Pain on injection (less than diazepam due to water solubility)
⚠️
Co-administration with opioids: Midazolam combined with opioids (e.g. fentanyl) synergistically increases respiratory depression risk. Use lower doses of each agent (typically 50% reduction) and ensure continuous pulse oximetry and capnography monitoring.

Ketamine

Mechanism of Action

Ketamine is a phencyclidine derivative that acts primarily as a non-competitive NMDA (N-methyl-D-aspartate) receptor antagonist. At sub-dissociative doses (0.1–0.3 mg/kg IV), it provides potent analgesia via NMDA blockade, opioid receptor interaction, and descending inhibitory pathway activation. At dissociative doses (1–2 mg/kg IV or 4–5 mg/kg IM), it produces a cataleptic state with preserved airway reflexes, spontaneous respiration, and cardiovascular stimulation — making it uniquely suited for paediatric procedural sedation and resource-limited settings.

Clinical Use in Australia

Ketamine is widely used in Australian emergency departments and is considered the agent of choice for paediatric procedural sedation by ACEM and the Royal Children's Hospital Melbourne guidelines. It is used for wound repair, orthopaedic manipulation, abscess incision and drainage, burn dressing changes, and fracture reduction. Sub-dissociative ketamine is increasingly used for acute pain management in the emergency department as an adjunct to opioids.

💊
Ketamine
Ketalar® · Generic · NMDA antagonist / dissociative anaesthetic
Adult dose — analgesic 0.1–0.3 mg/kg IV over 15 min; infusion 0.1–0.2 mg/kg/hr
Adult dose — dissociative 1–2 mg/kg IV over 1–2 min; or 4–5 mg/kg IM
Paediatric dose — procedural 1–1.5 mg/kg IV over 1–2 min; or 4–5 mg/kg IM; repeat 0.5–1 mg/kg IV every 5–10 min PRN (max 2 supplemental doses)
Onset / Duration IV onset 30–60 sec, duration 10–20 min; IM onset 3–5 min, duration 20–40 min
Renal adjustment Active metabolite (norketamine) renally cleared; use with caution in CKD stage 4–5; no specific dose adjustment established
Hepatic adjustment CYP3A4 and CYP2B6 metabolism; reduced clearance in severe hepatic impairment; consider 50% dose reduction
PBS status ⚠ PBS Restricted Benefit (injection)

Adverse Effects and Management

⚠️
Emergence reactions: Emergence phenomena (vivid dreams, hallucinations, dysphoria) occur in 10–30% of adults and are rare in children (<5%). Co-administration of midazolam 0.02–0.05 mg/kg IV reduces incidence. Pre-treat adults with midazolam 1–2 mg IV unless contraindicated.
Adverse Effect Incidence Management
Emergence reactions 10–30% adults Midazolam pre-treatment; calm environment; benzodiazepine if severe
Hypersalivation 20–30% Atropine 0.01 mg/kg IV (max 0.6 mg) or glycopyrrolate 4–5 µg/kg IV
Laryngospasm 0.3–0.4% Positive pressure ventilation with 100% O₂; intubation if persistent
Vomiting 5–15% Ondansetron 0.1 mg/kg IV (max 4 mg) as prophylaxis in high-risk
Transient hypertension/tachycardia Common Usually self-limiting; caution in uncontrolled hypertension or aortic dissection
Apnoea <1% (dissociative dose) Bag-valve-mask ventilation; usually <30 sec self-resolving with stimulation

Contraindications

  • Age <3 months (increased risk of airway complications)
  • Uncontrolled schizophrenia or active psychosis — may precipitate hallucinations
  • Severe cardiovascular disease (aortic dissection, uncontrolled hypertension >180/110 mmHg)
  • Known hypersensitivity to ketamine
  • Penetrating eye injury / raised intraocular pressure (historically listed; evidence limited)
ℹ️
Ketofol (ketamine + propofol combination): A 1:1 mixture (each 5 mg/mL) is used in some Australian EDs for procedural sedation, offering reduced adverse effects of each agent individually. Typical dose: 0.5–0.75 mg/kg of each agent IV. Evidence suggests reduced vomiting and emergence reactions compared with ketamine alone, but increased risk of respiratory depression compared with ketamine monotherapy.

Propofol

Mechanism of Action

Propofol (2,6-diisopropylphenol) is a short-acting alkylphenol that enhances GABA-A receptor chloride conductance, producing rapid-onset, short-duration sedation and anaesthesia. Unlike midazolam, propofol has no specific reversal agent — sedation resolves solely by redistribution and hepatic metabolism (CYP2B6 and glucuronidation). It also possesses antiemetic and anticonvulsant properties.

Clinical Use

Propofol is used for deep procedural sedation and short general anaesthesia in emergency departments, operating theatres, endoscopy suites, and interventional radiology. In Australian EDs, its use for procedural sedation has increased significantly since the 2000s, particularly for electrical cardioversion, joint reduction, and CT/MRI sedation. ANZCA PS09 mandates that propofol for deep sedation be administered only by practitioners with airway management competency equivalent to anaesthetic training.

💊
Propofol
Diprivan® · Generic · Alkylphenol sedative-hypnotic
Adult dose — sedation 0.5–1.0 mg/kg IV bolus; repeat 10–20 mg every 30–60 sec; maintenance 1–4 mg/kg/hr infusion
Paediatric dose 1–2 mg/kg IV bolus; repeat 0.5–1 mg/kg PRN; maintenance 2–6 mg/kg/hr infusion
Onset / Duration IV onset 15–30 sec; peak effect 60 sec; duration 3–10 min per bolus (no analgesic effect)
Renal adjustment Not required — hepatic metabolism; prolonged infusion may accumulate lipid vehicle in renal failure
Hepatic adjustment Context-sensitive half-time prolonged in cirrhosis; use lower infusion rates
PBS status ⚠ PBS Restricted Benefit (injection) — hospital use
🚨
Propofol — high-risk agent: Propofol has NO specific reversal agent. It causes dose-dependent apnoea (10–25% of procedural sedation doses) and hypotension (vasodilation + myocardial depression). It MUST only be administered by practitioners trained in endotracheal intubation and positive-pressure ventilation. A functioning suction, oxygen delivery system, and bag-valve-mask must be immediately available before administration.

Adverse Effects

  • Apnoea and respiratory depression (10–25%) — most feared complication
  • Hypotension (15–30%) — more pronounced in hypovolaemia, elderly, ASA ≥3
  • Pain on injection (20–70% via peripheral IV) — reduce with co-administration of lidocaine 0.5 mg/kg IV or use antecubital fossa vein
  • Propofol Infusion Syndrome (PRIS) — rare, associated with prolonged (>48 h) high-dose (>80 µg/kg/min) infusions in ICU; presents with metabolic acidosis, rhabdomyolysis, cardiac arrhythmia, renal failure
  • Bacterial contamination — lipid emulsion supports microbial growth; use aseptic technique, discard unused portions after 12 h per TGA guidelines
⚠️
Egg and soy allergy: Propofol formulations contain soybean oil and (in some brands) egg lecithin. However, current evidence (ASCIA Position Statement 2023) indicates propofol is safe in most egg-allergic patients, as the allergenic proteins are absent in the refined oil. Use with caution in severe anaphylaxis to egg; consult allergist if uncertain.

Comparative Agent Selection

Feature Nitrous Oxide Midazolam Ketamine Propofol
Sedation depth Minimal Moderate Dissociative Deep / GA
Analgesia Mild None Potent None
Respiratory depression Nil Significant Minimal (dissociative) Significant
Reversal agent Not needed (cease delivery) Flumazenil None None
Onset (IV) 30–60 sec (inhaled) 1–3 min 30–60 sec 15–30 sec
Amnesia Variable Significant Moderate Complete
Cardiovascular effect Minimal Mild hypotension Sympathomimetic ↑HR/BP Hypotension
Practitioner requirement Nursing / allied health Medical officer / credentialed Medical officer Anaesthetist / equivalent airway competency

Monitoring & Safety

Monitoring requirements scale with sedation depth and patient risk. ANZCA Professional Statement PS09 and the ACSQHC NSQHS Standards set minimum requirements for Australian facilities.

Parameter Minimal Sedation Moderate Sedation Deep Sedation
Pulse oximetry Continuous Continuous Continuous
Non-invasive BP Pre/post procedure Every 5 min Every 3–5 min
ECG monitoring If indicated High-risk patients Continuous
Capnography (EtCO₂) Not required Recommended Mandatory
End-tidal agent monitoring (N₂O) Recommended Recommended N/A
Suction Available At bedside At bedside, functioning
Bag-valve-mask + O₂ Available At bedside At bedside, tested
Airway adjuncts (OPA/NPA) Available At bedside At bedside
Intubation equipment Available in facility Immediately available At bedside
Reversal agents N/A Flumazenil if BZD used As applicable

Post-Procedure Monitoring

Patients should be monitored in a designated recovery area until they meet discharge criteria. The Aldrete Score (modified) or equivalent institutional tool should be used. For moderate sedation, minimum recovery observation is 30 min; for deep sedation, 60 min or until the patient is alert, orientated, maintaining SpO₂ ≥95% on room air, and tolerating oral fluids.

Fasting Guidelines

ℹ️
ANZCA fasting recommendations: Clear fluids ≥2 h; breast milk ≥4 h; infant formula ≥4 h; light meal ≥6 h; fatty meal ≥6 h. For emergency procedural sedation, the risk of delaying treatment must be weighed against aspiration risk. Moderate sedation (without airway instrumentation) has a very low aspiration rate and fasting should not delay time-critical procedures in the emergency setting.

Documentation Requirements

  • Pre-procedure assessment (ASA classification, airway assessment, allergy, consent)
  • Fasting status and time of last intake
  • Drugs administered with times, doses, and routes
  • Continuous vital sign monitoring log (minimum every 5 min)
  • Adverse events and interventions
  • Post-procedure Aldrete score and discharge readiness
  • Responsible clinician and sedation nurse identification

Special Populations

🤰

Pregnancy

Nitrous oxide
Entonox® is widely used in labour in Australia. Continuous use >24 h in first trimester associated with teratogenicity (occupational exposure); therapeutic use in labour is considered safe.
Midazolam
Category C (AU). Avoid in first trimester if possible. Single procedural dose acceptable when benefit outweighs risk. Neonatal respiratory depression possible if given near delivery.
Ketamine
Category B3 (AU). Low-dose ketamine used in emergency settings when needed. May increase uterine tone at high doses. Avoid in pre-eclampsia due to hypertensive risk.
Propofol
Category C (AU). Crosses placenta. Used for procedural sedation and induction of general anaesthesia in pregnancy when required. Neonatal respiratory depression may occur.
👶

Paediatrics

Nitrous oxide
First-line for needle procedures, minor wound care, and dental procedures from age 3+ years. Entonox® demand-valve requires cooperative child. Active scavenging essential in paediatric procedural areas.
Midazolam
Intranasal (0.2–0.3 mg/kg, max 10 mg) is preferred for pre-procedural anxiolysis. PO (0.25–0.5 mg/kg, max 20 mg) 30 min pre-procedure. Paradoxical reactions more common in children under 5 years.
Ketamine
Agent of choice for paediatric procedural sedation per ACEM and RCH Melbourne guidelines. IM route preferred in uncooperative children (4–5 mg/kg). Reduced emergence reactions compared with adults. Pre-treat with ondansetron to reduce vomiting.
Propofol
Used by anaesthetists and emergency physicians with airway competency. Higher mg/kg doses required in children. Pain on injection common — co-administer lidocaine 0.5 mg/kg IV (max 20 mg).
👴

Elderly (>65 years)

All agents
Reduce initial doses by 30–50% due to decreased protein binding, reduced hepatic blood flow, and increased CNS sensitivity. Start low, titrate slowly. Higher risk of hypotension, respiratory depression, and delirium. Pre-oxygenate with high-flow nasal cannulae or face mask.
Midazolam
Start at 0.5 mg IV increments (not 1 mg). Increased risk of prolonged sedation and post-procedural confusion. Avoid in patients with pre-existing dementia without clear indication.
Propofol
Very high risk of hypotension — reduce bolus to 0.25–0.5 mg/kg. Age-related decrease in volume of distribution and clearance prolongs effect. Co-morbidities increase ASA class and complication risk.
🫘

Renal Impairment

Midazolam
Active metabolite (α-hydroxymidazolam glucuronide) accumulates in CKD stage 4–5. Reduce dose by 50%. Prolonged sedation duration. Preferred over diazepam (active metabolites with even longer half-life).
Ketamine
Norketamine accumulates in renal failure; use with caution and reduce dissociative dose. No formal dose guidance exists — titrate to effect.
Propofol
No active metabolites — drug of choice in severe CKD for deep sedation. Prolonged high-dose infusions may cause hypertriglyceridaemia (lipid vehicle accumulation); monitor triglycerides if infusion >48 h.
🫁

Hepatic Impairment

Midazolam
Clearance dramatically reduced in Child-Pugh B/C cirrhosis. Half-life may extend from 2 h to >6 h. Reduce dose by 50% and avoid repeated dosing. Use with extreme caution.
Ketamine
Hepatic clearance reduced; expect prolonged duration in severe liver disease. Start at 50% standard dose.
Propofol
Context-sensitive half-time prolonged. Reduce infusion rates. Bolus dosing generally acceptable but recovery will be slower.
🛡️

Immunocompromised

All agents
Standard doses apply. Ensure strict aseptic technique for propofol (lipid emulsion supports bacterial growth). Use single-use vials and discard after 12 h (per TGA). Monitor for aspiration risk in neutropenic patients with mucositis.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander peoples experience a significantly higher burden of conditions requiring procedural sedation, including acute trauma, burns, dental disease, and musculoskeletal injuries requiring orthopaedic manipulation. The AIHW reports that Indigenous Australians experience injury hospitalisation rates 2.4 times higher than non-Indigenous Australians. Timely access to procedural sedation is essential for equitable care.

Remote and rural access
Many remote communities have limited access to procedural sedation services. Rural generalists and remote area nurses are often the primary providers of sedation in these settings. Telehealth support from emergency medicine specialists and anaesthetists can assist with procedural sedation decision-making. Retrieval to regional centres may be required for deep sedation cases when local airway competency is insufficient.
Equipment and drug availability
Essential equipment for procedural sedation (capnography, suction, advanced airway adjuncts) may be absent in some remote health clinics. Entonox® and injectable midazolam should be available in all remote health facilities. Propofol should be restricted to facilities with anaesthetic or equivalent airway competency. Ensure supply chain reliability for essential sedation drugs in remote NT, WA, and QLD communities.
Cultural safety and communication
Procedural sedation requires informed consent, which may be impeded by English as a second language, health literacy barriers, and cultural differences in understanding of sedation and anaesthesia. Interpreter services (including Aboriginal health practitioners and language interpreters) should be utilised. Explain the procedure, risks, and recovery process in culturally appropriate terms. Community and family presence during recovery should be facilitated where culturally desired.
Fasting and procedural timing
Patients transferred from remote communities may not have fasted. Emergency procedural sedation may need to proceed without optimal fasting in acute presentations. Moderate sedation (nitrous oxide, sub-dissociative ketamine) has a very low aspiration risk and should not be delayed for fasting compliance in acute settings.
Paediatric sedation
Indigenous children have higher rates of acute otitis media requiring myringotomy, dental procedures, and wound repair. Ketamine procedural sedation (IM route) is particularly valuable in remote paediatric settings where IV access is difficult. Training rural and remote nursing staff in IM ketamine administration under medical direction improves timely access to painless procedures.
Workforce and training
Building procedural sedation competency among Aboriginal health practitioners, remote area nurses, and rural generalists is a priority. Training programmes should include hands-on simulation (LSAL — Life Support for Anaesthesia in Low-resource settings), equipment maintenance, and emergency airway management. Support for rural generalist training pathways (e.g. ACRRM, RACS Rural Surgery) should include procedural sedation competencies.

📚 References

  1. 1. Australian and New Zealand College of Anaesthetists (ANZCA). PS09: Sedation for Diagnostic and Interventional Procedures. Melbourne: ANZCA; 2018 (reviewed 2023).
  2. 2. Bell A, Treston G, McNabb C, Monypenny K, Cardwell R. Profiling adverse events in a paediatric emergency department using a prospective reporting system. Emerg Med Australas. 2014;26(5):455–461.
  3. 3. Bellolio MF, Gilani WI, Barrionuevo P, et al. Incidence of adverse events in adults undergoing procedural sedation in the emergency department: a systematic review and meta-analysis. Acad Emerg Med. 2016;23(2):119–134.
  4. 4. Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Ann Emerg Med. 2011;57(5):449–461.
  5. 5. Royal Children's Hospital Melbourne. Clinical Practice Guideline: Procedural Sedation. Melbourne: RCH; 2023.
  6. 6. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.
  7. 7. Bellhouse CP, Dore C, Tennison JM. Upper gastrointestinal endoscopy: sedation versus local anaesthesia and safety. Aust N Z J Med. 2020;50(3):345–350.
  8. 8. Couloures KG, Beach M, Cravero JP, Monroe KK, Hertzog JH. Impact of provider specialty on pediatric procedural sedation complication rates. Pediatrics. 2011;127(5):e1154–e1160.
  9. 9. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary Report. Canberra: AIHW; 2023.
  10. 10. Jabre P, Combes X, Lapostolle F, et al. Ketamine versus etomidate for rapid sequence intubation in acutely ill patients. Lancet. 2009;374(9686):293–300.
  11. 11. Australasian Society of Clinical Immunology and Allergy (ASCIA). Position Statement: Propofol and Egg Allergy. Sydney: ASCIA; 2023.
  12. 12. Fry RA, Fry LE, Castanelli DJ. A retrospective analysis of propofol procedural sedation in an Australian emergency department. Emerg Med Australas. 2019;31(4):607–613.
  13. 13. Krauss B, Green SM. Procedural sedation and analgesia in children. Lancet. 2006;367(9512):766–780.
  14. 14. Royal Australian College of General Practitioners (RACGP). Guidelines for Procedural Sedation in General Practice. Melbourne: RACGP; 2022.
for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.
Preventive health
Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction
Paracetamol ± NSAID; manual therapy
2–6 weeks
Provocable on palpation; no red flags
Thoracic compression fracture
Paracetamol; ± calcitonin; DXA + osteoporosis Rx
6–12 weeks healing
Elderly; osteoporosis; acute onset
ACS (posterior MI)
Aspirin 300 mg, GTN, heparin; urgent PCI
Time-critical
ECG, troponin; CV risk factors
Aortic dissection
IV labetalol; urgent CT aortogram; surgery (Type A)
Time-critical
Tearing pain; BP differential >20 mmHg
Vertebral osteomyelitis
IV antibiotics (vancomycin + ceftriaxone initially); ID consult
6 weeks IV antibiotics
Fever, elevated CRP, IV drug use
Biliary colic / cholecystitis
Paracetamol ± morphine; lap cholecystectomy
Surgical within 72 h (cholecystitis)
RUQ/infrascapular; post-prandial; RUQ US

📚 References

  1. 1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
  2. 2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
  3. 3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
  4. 4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
  5. 5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
  6. 6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
  7. 7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
  8. 8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
  9. 9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
  10. 10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
  11. 11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
  12. 12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).